Lou Gehrig's Disease - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Lou Gehrig's disease - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Lou Gehrig's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Lou Gehrig's disease Understanding

Lou Gehrig's disease: Overview

Lou Gehrig's disease is often called Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive, degenerative disease that destroys the nerve cells that control voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking.It affects nerves in the brain and spinal cord that control muscles. The result is progressive muscle weakness and incoordination, causing difficulty with mobility, speaking, swallowing and breathing. Gradually the body becomes paralyzed, which means that the muscles no longer work. The exact cause is unknown, but environmental and genetic factors may be involved. ALS tends to strike in mid-life between the ages of 40 and 60, but others can develop the disease. ALS can be classified as either sporadic or familial. Sporadic ALS occurs randomly, there is no clear factor or cause. Familial ALS is inherited due to change in gene.

"Lou Gehrig's disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lou Gehrig's disease pipeline landscape is provided which includes the disease overview and Lou Gehrig's disease treatment guidelines. The assessment part of the report embraces, in depth Lou Gehrig's disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lou Gehrig's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Lou Gehrig's disease R&D. The therapies under development are focused on novel approaches to treat/improve Lou Gehrig's disease.

Lou Gehrig's disease Emerging Drugs Chapters

This segment of the Lou Gehrig's disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lou Gehrig's disease Emerging Drugs

- BIIB067: Ionis Pharmaceuticals, Inc

BIIB067 (Tofersen) is a second generation antisense oligonucleotide designed to reduce the production of superoxide dismutase 1 (SOD1), the cause of a genetic form of ALS, referred to as SOD1-ALS, that results from mutations in the SOD1 gene. Tofersen is currently in a Phase 3 clinical trial in SOD1-ALS patients led by Ionis Pharmaceuticals, Inc in collaboration with Biogen.

- Arimoclomol: Orphazyme

Orphazyme is developing arimoclomol in four indications: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM). Arimoclomol has been shown to increase the production of cell protective HSPs. This increase in the production of naturally occurring HSPs inside the cells, reduces protein misfolding and aggregation and improves lysosomal function. Arimoclomol is currently in its phase III of development.

- ALZT-OP1a: AZTherapies, Inc.

AZTherapies, Inc. a biopharmaceutical company leading the advanced clinical trials to treat neuroinflammatory diseases, ALZT-OP1a is currently in Phase 2a stage of development examining the safety and efficacy in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS). ALZT-OP1a is the company's proprietary inhaled formulation of cromolyn, engineered to improve blood brain barrier permeability and bioavailability.

- RNS60: Revalesio Corporation.

RNS60 is a leading clinical drug candidate to treat amyotrophic lateral sclerosis (ALS) and other neurological diseases. It can be administered by IV infusion or inhalation (nebulization).RNS60 is currently being tested in a placebo-controlled, multicenter ALS Phase 2 study. RNS60 acts on mitochondria and activates intracellular signaling pathways that have anti-inflammatory effects and promote cellular survival and differentiation. Thereby, RNS60 protects neurons and oligodendrocytes, and helps the immune system restore homeostasis through modulation of immune cell activity in the central nervous system and throughout the body.

Further product details are provided in the report……..

Lou Gehrig's disease: Therapeutic Assessment

This segment of the report provides insights about the different Lou Gehrig's disease drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Lou Gehrig's disease

There are approx. 30+ key companies which are developing the therapies for Lou Gehrig's disease. The companies which have their Lou Gehrig's disease drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals Inc.

- Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II and phase I/II )

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Lou Gehrig's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Intravenous

- Subcutaneous

- Inhalation

- Molecule Type

Products have been categorized under various Molecule types such as

- Peptides

- Small molecule

- Oligonucleotides

- Gene Therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lou Gehrig's disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lou Gehrig's disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lou Gehrig's disease drugs.

Lou Gehrig's disease Report Insights

- Lou Gehrig's disease Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Lou Gehrig's disease Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Lou Gehrig's disease drugs?

- How many Lou Gehrig's disease drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lou Gehrig's disease?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Lou Gehrig's disease therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Lou Gehrig's disease and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Ionis Pharmaceuticals Inc.

- AZTherapies Inc.

- Revalesio Corporation.

- AB science

- Biogen

- Hoffmann-La Roche

- Mitsubishi Tanabe Pharma Development America Inc.

- Orphazyme

- Q Therapeutics, Inc.

- Genuv Inc.

- Orion Corporation

- AL-S Pharma

- Immunity Pharma Ltd.

- Everfront Biotech Co., Ltd.

Key Products

- IPL344

- BIIB078

- MT-1186

- Levosimendan

- HK-001

- IPL344

- Arimoclomol

- Dexpramipexole

- BIIB078

- Olesoxime

- ALZT-OP1a

- Masitinib

Lou Gehrig's Disease - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Lou Gehrig's disease: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Lou Gehrig's disease - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Lou Gehrig's disease companies' collaborations, Licensing, Acquisition -Deal Value Trends
Lou Gehrig's disease Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
BIIB067: Ionis Pharmaceuticals, Inc
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
ALZT-OP1a: AZTherapies, Inc.
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
BIIB100: Karyopharm Therapeutics
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Lou Gehrig's disease Key Companies
Lou Gehrig's disease Key Products
Lou Gehrig's disease- Unmet Needs
Lou Gehrig's disease- Market Drivers and Barriers
Lou Gehrig's disease- Future Perspectives and Conclusion
Lou Gehrig's disease Analyst Views
Lou Gehrig's disease Key Companies
Appendix

List of Tables

Table 1 Total Products for Lou Gehrig's disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Lou Gehrig's disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Autism Spectrum Disorder Market Growth (Status and Outlook) 2021-2026
    Published: 17-Mar-2021        Price: US 3660 Onwards        Pages: 117
    According to this latest study, the 2021 growth of Autism Spectrum Disorder will have significant change from previous year. By the most conservative estimates of global Autism Spectrum Disorder market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 384400 million in 2020. Over the next five years the Autism Spectrum Disorder market will register a 17.9% CAGR in terms of revenue, the global market size will reach US$ 743920 million by 2026. ......
  • Global Gabapentin Market Growth 2021-2026
    Published: 16-Mar-2021        Price: US 3660 Onwards        Pages: 159
    According to this latest study, the 2021 growth of Gabapentin will have significant change from previous year. By the most conservative estimates of global Gabapentin market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1482.5 million in 2020. Over the next five years the Gabapentin market will register a 1.9% CAGR in terms of revenue, the global market size will reach US$ 1596.4 million by 2026. This report presents a comprehensi......
  • Global Restless Legs Syndrome Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
    Published: 16-Mar-2021        Price: US 3500 Onwards        Pages: 116
    Based on the Restless Legs Syndrome market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analy......
  • Global Gabapentin Market Research Report 2021
    Published: 17-Feb-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Capsule - Tablet Segment by Application - Epilepsy - Neuropathic Pain - Restle......
  • Global Gabapentin Market Analysis 2016-2020 and Forecast 2021-2026
    Published: 13-Feb-2021        Price: US 2980 Onwards        Pages: 85
    Snapshot Gabapentin is an anti-epileptic medication, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. The global Gabapentin market size is estimated at xxx million USD with a CAGR xx% from 2016-2020 and is expected to reach xxx Million USD in 2021 with a CAGR xx% from 2021 to 2026. The report begins from overview of Industry Chain structure, and describes industry environment, then ana......
  • Global Biopolar Disorder Therapeutics Market Research Report 2021
    Published: 10-Feb-2021        Price: US 2900 Onwards        Pages: 92
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Mood Stabilizers - Antipsychotic Drugs - Antidepressant Drugs - Others Segment by App......
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pi......
  • Chronic Traumatic Encephalopathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geogra......
  • Small Fiber Neuropathy - Pipeline Insight, 2021
    Published: 10-Feb-2021        Price: US 1500 Onwards        Pages: 60
    DelveInsight's, "Small Fiber Neuropathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs